{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:15:51Z","timestamp":1781842551966,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.pupt.2014.02.002","type":"journal-article","created":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T20:31:18Z","timestamp":1393705878000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: Meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"29","author":[{"given":"Guang-Ying","family":"Zhuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiang-Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Ya-Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Si-Te","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2014.02.002_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/pgmj.2009.091041","article-title":"Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century","volume":"86","author":"Goeminne","year":"2010","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.pupt.2014.02.002_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4046\/trd.2012.73.5.249","article-title":"Bronchiectasis","volume":"73","author":"Kim","year":"2012","journal-title":"Tuberc Respir Dis"},{"key":"10.1016\/j.pupt.2014.02.002_bib3","first-page":"809","article-title":"Bronchiectasis \u2013 diagnosis and treatment","volume":"108","author":"Rademacher","year":"2011","journal-title":"Dtsch Arzteblatt Int"},{"key":"10.1016\/j.pupt.2014.02.002_bib4","first-page":"338","article-title":"Effect of macrolide on lung function and computed tomography (CT) score in non-cystic fibrosis bronchiectasis","volume":"67","author":"Goeminne","year":"2012","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.pupt.2014.02.002_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.rmed.2006.11.008","article-title":"Aetiology in adult patients with bronchiectasis","volume":"101","author":"Shoemark","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.02.002_bib6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201302-0240ED","article-title":"Microbes in bronchiectasis: the forest or the trees?","volume":"187","author":"Harris","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.02.002_bib7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1378\/chest.08-0776","article-title":"Bronchiectasis","volume":"134","author":"O'Donnell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.02.002_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/adc.2007.130054","article-title":"Non-cystic fibrosis bronchiectasis: its diagnosis and management","volume":"95","author":"Stafler","year":"2010","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"10.1016\/j.pupt.2014.02.002_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/QCO.0b013e328335af91","article-title":"Respiratory infection in noncystic fibrosis bronchiectasis","volume":"23","author":"Zoumot","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.pupt.2014.02.002_bib10","doi-asserted-by":"crossref","first-page":"584262","DOI":"10.1155\/2012\/584262","article-title":"Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics","volume":"2012","author":"Steel","year":"2012","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.pupt.2014.02.002_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in\u00a0vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pupt.2014.02.002_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003495-200969040-00002","article-title":"Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents","volume":"69","author":"Ilowite","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2014.02.002_bib13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl.\u00a09A","key":"10.1016\/j.pupt.2014.02.002_bib14","first-page":"12S","article-title":"Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases","volume":"117","author":"Kudoh","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.pupt.2014.02.002_bib15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.prrv.2009.12.003","article-title":"The role of azithromycin in patients with cystic fibrosis","volume":"11","author":"Yousef","year":"2010","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.pupt.2014.02.002_bib16","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.rmed.2008.06.005","article-title":"Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis","volume":"102","author":"Anwar","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.02.002_bib17","first-page":"CD001392","article-title":"Prolonged antibiotics for purulent bronchiectasis in children and adults","author":"Evans","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pupt.2014.02.002_bib18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(07)60235-9","article-title":"Effect of\u00a0azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study","volume":"369","author":"Malhotra-Kumar","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2014.02.002_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijantimicag.2009.05.008","article-title":"Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005","volume":"34","author":"Karlowsky","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pupt.2014.02.002_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1183\/09031936.99.13236199","article-title":"A\u00a0pilot study of low-dose erythromycin in bronchiectasis","volume":"13","author":"Tsang","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.02.002_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2014.02.002_bib22","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.pupt.2014.02.002_bib23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.pupt.2014.02.002_bib24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ppul.1076","article-title":"Anti-inflammatory effects of macrolides in lung disease","volume":"31","author":"Jaffe","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.pupt.2014.02.002_bib25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.02.002_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pupt.2009.03.002","article-title":"Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis","volume":"22","author":"Florescu","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2014.02.002_bib27","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1378\/chest.125.2_suppl.41S","article-title":"The effects of macrolides on inflammatory cells","volume":"125","author":"Tamaoki","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.02.002_bib28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pharmthera.2007.11.001","article-title":"Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action","volume":"117","author":"Shinkai","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pupt.2014.02.002_bib29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00003495-200767070-00002","article-title":"Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?","volume":"67","author":"King","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2014.02.002_bib30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/resp.12130","article-title":"Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis.","volume":"18","author":"Diego","year":"2013","journal-title":"Respirology (Carlton, Vic)"},{"key":"10.1016\/j.pupt.2014.02.002_bib31","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.rmed.2011.01.009","article-title":"Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations","volume":"105","author":"Serisier","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.02.002_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.idc.2004.04.010","article-title":"Macrolides and ketolides: azithromycin, clarithromycin, telithromycin","volume":"18","author":"Zuckerman","year":"2004","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.pupt.2014.02.002_bib33","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1378\/chest.128.2.739","article-title":"Quality-of-life determinants in patients with clinically stable bronchiectasis","volume":"128","author":"Martinez-Garcia","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.02.002_bib34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1183\/09031936.00003709","article-title":"Mortality in bronchiectasis: a long-term study assessing the factors influencing survival","volume":"34","author":"Loebinger","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.02.002_bib35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Martinez-Garcia","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.02.002_bib36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1378\/chest.07-1631","article-title":"Airway inflammation in cystic fibrosis","volume":"133","author":"Elizur","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.02.002_bib37","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.pupt.2014.02.002_bib38","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dkr040","article-title":"Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review","volume":"66","author":"Cai","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2014.02.002_bib39","first-page":"774","article-title":"Azithromycin and the risk of cardiovascular death","volume":"367","author":"Pires dos Santos","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2014.02.002_bib40","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/eurheartj\/ehi312","article-title":"Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death","volume":"26","author":"Straus","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pupt.2014.02.002_bib41","first-page":"75","article-title":"Immunomodulatory effects of macrolide antibiotics \u2013 part 2: advantages and disadvantages of long-term, low-dose macrolide therapy","volume":"81","author":"Altenburg","year":"2011","journal-title":"Respir Int Rev Thorac Dis"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914000212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914000212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T18:27:50Z","timestamp":1716575270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553914000212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1094553914000212"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2014.02.002","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: Meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2014.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}